IL315832A - Psychoactive drugs and their use to treat psychiatric and neurological conditions and disorders - Google Patents

Psychoactive drugs and their use to treat psychiatric and neurological conditions and disorders

Info

Publication number
IL315832A
IL315832A IL315832A IL31583224A IL315832A IL 315832 A IL315832 A IL 315832A IL 315832 A IL315832 A IL 315832A IL 31583224 A IL31583224 A IL 31583224A IL 315832 A IL315832 A IL 315832A
Authority
IL
Israel
Prior art keywords
psychoactive
medicines
disorders
neurological conditions
treating psychiatric
Prior art date
Application number
IL315832A
Other languages
English (en)
Hebrew (he)
Inventor
Blake Mandell
Martin Stogniew
Jennifer Louise Schmidt
Markus Seelig
Original Assignee
Transcend Therapeutics Inc
Blake Mandell
Martin Stogniew
Jennifer Louise Schmidt
Markus Seelig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/074369 external-priority patent/WO2023015154A1/en
Application filed by Transcend Therapeutics Inc, Blake Mandell, Martin Stogniew, Jennifer Louise Schmidt, Markus Seelig filed Critical Transcend Therapeutics Inc
Publication of IL315832A publication Critical patent/IL315832A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315832A 2022-03-31 2023-02-02 Psychoactive drugs and their use to treat psychiatric and neurological conditions and disorders IL315832A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325757P 2022-03-31 2022-03-31
US202263328343P 2022-04-07 2022-04-07
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US202363437000P 2023-01-04 2023-01-04
PCT/US2023/012196 WO2023191952A1 (en) 2022-03-31 2023-02-02 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (1)

Publication Number Publication Date
IL315832A true IL315832A (en) 2024-11-01

Family

ID=88203364

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315832A IL315832A (en) 2022-03-31 2023-02-02 Psychoactive drugs and their use to treat psychiatric and neurological conditions and disorders

Country Status (10)

Country Link
EP (1) EP4499066A4 (https=)
JP (1) JP2025510790A (https=)
KR (1) KR20240165982A (https=)
CN (1) CN119095593A (https=)
AU (1) AU2023241546A1 (https=)
CA (1) CA3254727A1 (https=)
IL (1) IL315832A (https=)
MX (1) MX2024012095A (https=)
TW (1) TW202345789A (https=)
WO (1) WO2023191952A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379978A (zh) * 2022-10-20 2025-07-25 创见疗法股份有限公司 苯乙胺和卡西酮及其立体异构体与其前体的制备

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) * 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
EP2931291B1 (en) * 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) * 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) * 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
AU2022330718B2 (en) * 2021-08-20 2026-02-19 Pharmala Biotech Inc. Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Also Published As

Publication number Publication date
MX2024012095A (es) 2025-01-09
KR20240165982A (ko) 2024-11-25
CN119095593A (zh) 2024-12-06
WO2023191952A1 (en) 2023-10-05
CA3254727A1 (en) 2023-10-05
JP2025510790A (ja) 2025-04-15
TW202345789A (zh) 2023-12-01
EP4499066A4 (en) 2026-02-18
AU2023241546A1 (en) 2024-10-17
EP4499066A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL310334A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
CA208374S (en) Mouth tape for treating sleep disorders
HUE073599T2 (hu) Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére
IL315832A (en) Psychoactive drugs and their use to treat psychiatric and neurological conditions and disorders
IL307607A (en) Tetracyclic compounds for the treatment of brain disorders
GB202104590D0 (en) Treatment of the central nervous system
KR102591782B9 (ko) 뇌신경계질환 예방 또는 치료용 약학적 조성물
GB201914034D0 (en) Treatment of neurological disorders
GB202004498D0 (en) Activity-dependent gene therapy for neurological disorders
IL321201A (en) Methods for treating neurological disorders
IL313539A (en) Methods for treating neurological disorders
CA3294471A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120964A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
IL316269A (en) History of pyridine for the treatment of psychiatric disorders
HK40112016A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
IL311854A (en) Preparations and methods for the treatment of neurological disorders with combination products
EP4229035A4 (en) INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES
CA208376S (en) Mouth tape for treating sleep disorders
IL311852A (en) Preparations and methods for the treatment of neurological disorders
PL4135840T3 (pl) Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
IL319150A (en) Heteroaromatic compounds for the treatment of neurological disorders
GB202203627D0 (en) Agents for treating complement-related disorders
CA3286002A1 (en) Antisense oligonucleotides for the treatment of neurological disorders